Core Insights - Scienture Holdings, Inc. has formalized a commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement, enhancing formulary access for its product Arbli, which targets health plans covering over 100 million lives [1] - Arbli is FDA-approved for treating hypertension in patients over six years old and for reducing stroke risk in patients with hypertension and left ventricular hypertrophy, as well as treating diabetic nephropathy in certain type 2 diabetes patients [2] - Arbli is the first and only FDA-approved ready-to-use oral liquid losartan in the U.S., offering advantages such as reduced dosing volume and long-term shelf life at room temperature [3] Market Context - The U.S. losartan market is valued at approximately $256 million in annual sales with a prescription volume of 71 million, with all currently marketed products available only in oral solid form [4] - Scienture recently announced a registered direct offering of 3.225 million shares at $1.20 per share, generating gross proceeds of about $3.9 million [4] - As of the latest check, SCNX stock was down 4.01% at $0.94 during the premarket session [4]
EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market